Latest News

Yale Cancer Center annual Conclave in New Haven, March 26, 2024 include research and clinical awards. The four research awards are for: Clinical Cancer Research, Translational Science Research, Population Science Research, and Basic Cancer Research. Nine other awards are granted, including the Ruth McCorkle Oncology Advanced Practice Provider Award, the Class of '61 Cancer Research Awards, Clinical Excellence Award, Mentorship Excellence Award, Teaching Excellence Award, Service Excellence Award, Director's Awards, the Leadership in Diversity, Equity & Inclusion Award and the Lifetime Achievement Award.

Katerina Politi, PhD, Professor of Pathology; Co-Leader, Cancer Signaling Networks; and Scientific Director for the Center for Thoracic Cancers, is one of five individuals newly elected to the American Association for Cancer Research (AACR) Board of Directors.

Last Friday during Yale Cancer Center Grand Rounds, we welcomed Pasi A. Jänne, MD, PhD, Director of the Lowe Center for Thoracic Oncology and Professor of Medicine, Harvard Medical School; David M. Livingston, MD, Chair at Dana-Farber Cancer Institute, as guest presenter of the Paul Calabresi, MD, Memorial Lectureship, hosted by Dr. Roy Herbst, Deputy Director of Yale Cancer Center and Smilow Cancer Hospital.

Yale Team Shares Importance of Lung Cancer Screening at Community Event at Q House in New Haven.

Paul Stockhammer, MD, PhD, discusses research into the association between alterations in multiple tumor suppressor genes and poorer outcomes in patients with EGFR-mutant lung cancer, which was presented at the 2023 ASCO Annual Meeting.

A research team co-led by Dr. Katerina Politi found how mSWI/SNF complexes mediate resistance of lung adenocarcinomas to osimertinib and other tyrosine kinase inhibitors.

DIEP (deep inferior epigastric perforator), in which abdominal tissue is transplanted to the chest without using abdominal muscle, may soon be less available. Why? The Centers for Medicare and Medicaid Services (CMS) is planning to eliminate the billing codes for this and other specialized breast reconstruction procedures on Dec. 31, 2024. This should not be the case: women facing breast cancer need all the best reconstruction options readily available. This is deeply personal for me.

The American Society for Investigative Pathology features Katerina Politi, PhD, Associate Professor of Pathology, during Women in Pathology Month.

Targeted therapies and immune checkpoint inhibitors have transformed the treatment landscape for non–small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have contributed to an overall decline in lung cancer–related mortality, and as they move into the early-stage setting, more dramatic improvements in outcomes are expected. However, combatting TKI resistance in NSCLC is largely an unmet challenge. Tissue next-generation sequencing and plasma circulating tumor DNA–based assays have emerged as concurrent methods to identify targetable mechanisms of resistance to TKIs at the time of clinical progression, while antibody-drug conjugates represent a promising therapeutic class for the treatment of TKI-resistant NSCLC.